HB8857, the Next GEN Act of 2026, would amend the Social Security Act’s Drug Price Negotiation Program to treat a new category of medicines—engineered cyclic peptides—more favorably for negotiation timing purposes. Under current law, qualifying single-source drugs generally receive a 7-year period before they can be selected for negotiation; this bill would extend that period to 11 years for engineered cyclic peptides that meet the bill’s definition.
The bill defines engineered cyclic peptides as non-naturally derived, amino-acid-based polymers with at least one cyclic structure, no more than 40 amino acids, identified through genetically encoded library screening, and administered orally, by inhalation, or by another self-administered route. The change would apply to future drug lists published under the Medicare drug negotiation provisions, meaning it would affect how certain newly developed therapies are treated under federal price negotiation rules.
If enacted, the bill would amend Section 1192(e) of the Social Security Act and create a statutory carve-out within the Medicare Drug Price Negotiation Program for engineered cyclic peptides. The practical effect would be to delay the point at which these drugs become eligible for negotiation from 7 years to 11 years, potentially allowing manufacturers a longer period of market pricing before federal negotiation begins. The bill would primarily affect drug manufacturers developing this class of therapies, as well as Medicare and beneficiaries who could face delayed negotiation-driven price reductions for covered drugs in this category.
The available context suggests generally supportive sentiment among the bill’s sponsors and likely industry-aligned advocates, since the measure is framed as a targeted adjustment for a specific emerging drug class rather than a broad rollback of negotiation authority. There is no recorded committee debate or vote history in the provided materials, so no formal opposition or bipartisan division is documented here. The introduction by multiple House members indicates at least some cross-member interest in the proposal.
The main point of contention is likely the policy tradeoff between encouraging innovation in next-generation peptide medicines and preserving the government’s ability to negotiate lower prices sooner. Supporters would argue that engineered cyclic peptides are a distinct, difficult-to-develop class of medicines that merit a longer exclusivity-like runway before negotiation. Critics would likely view the bill as a special exemption that weakens Medicare’s drug price negotiation leverage and could delay savings for patients and taxpayers. No specific objections or amendments are included in the provided record.